Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37363867

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2023 Sep 14
First author
Huber H

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2023 Sep 14;142(11):941-943. doi: 10.1182/blood.2023021284.
    note
    Source null
    related pmid
    37707873
    relationship
    Comment in

Authors and identifiers

  1. name
    Huber H
    type
    Author
  2. name
    Tausch E
    type
    Author
  3. name
    Schneider C
    type
    Author
  4. name
    Edenhofer S
    type
    Author
  5. name
    von Tresckow J
    type
    Author
  6. name
    Robrecht S
    type
    Author
  7. name
    Giza A
    type
    Author
  8. name
    Zhang C
    type
    Author
  9. name
    Fürstenau M
    type
    Author
  10. name
    Dreger P
    type
    Author
  11. name
    Ritgen M
    type
    Author
  12. name
    Illmer T
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Huber H
    type
    Author
  2. name
    Tausch E
    type
    Author
  3. name
    Schneider C
    type
    Author
  4. name
    Edenhofer S
    type
    Author
  5. name
    von Tresckow J
    type
    Author
  6. name
    Robrecht S
    type
    Author
  7. name
    Giza A
    type
    Author
  8. name
    Zhang C
    type
    Author
  9. name
    Fürstenau M
    type
    Author
  10. name
    Dreger P
    type
    Author
  11. name
    Ritgen M
    type
    Author
  12. name
    Illmer T
    type
    Author
bibliography ids
  1. nci-bib-883b38c8370a0e790cc8755d
book metadata
content sha256
43eb5095a588628e96e5bcc0b4714e3a7deb2a84fa2343a5c83ae852ff148cf1
document type
citation
dois
  1. 10.1182/blood.2023020013
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:37363867
immutable id
pubmed:37363867@43eb5095a588628e96e5bcc0b4714e3a7deb2a84fa2343a5c83ae852ff148cf1
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
11
name
Blood
nlm unique id
7603509
pages
961-972
volume
142
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2023 Sep 14;142(11):941-943. doi: 10.1182/blood.2023021284.
    note
    Source null
    related pmid
    37707873
    relationship
    Comment in
outcomes validated
false
pmid
37363867
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
6314ec10f8ac81d0716c3804e6be1f4e2643957f966e93bd3b8be7757711fcbb
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 Sep 14
precision
day
year
2023
publication types
  1. Multicenter Study
  2. Journal Article
  3. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37363867/
title
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.

Preserved source evidence · Not medical advice